Investigation Launched into MoonLake Immunotherapeutics for Potential Securities Claims

Strategic Insights -

MoonLake Immunotherapeutics, a biotech company listed on NASDAQ (NASDAQ: MLTX), is under investigation by the Rosen Law Firm for alleged securities fraud. The investigation stems from a press release issued on September 29, 2025, announcing disappointing results from the VELA-2 trial, which led to a 89.9% plunge in the company's stock price. The Rosen Law Firm is preparing a class action lawsuit on behalf of investors who may have suffered losses as a result of MoonLake's allegedly misleading business information. Investors who purchased MoonLake securities may be entitled to compensation through a contingency fee arrangement.

Key Takeaways:

  • The Rosen Law Firm is investigating potential securities claims against MoonLake Immunotherapeutics on behalf of shareholders who may have suffered losses due to allegedly misleading business information.
  • The investigation follows a press release issued by MoonLake on September 29, 2025, announcing disappointing results from the VELA-2 trial.
  • The company's stock price plummeted 89.9% on September 29, 2025, after the announcement.
  • The Rosen Law Firm has a track record of success in securities class actions, having achieved the largest settlement against a Chinese company at the time and ranking No. 1 by ISS Securities Class Action Services in 2017.
  • The firm has recovered hundreds of millions of dollars for investors and has a team of attorneys recognized by Lawdragon and Super Lawyers.

Statistics:

  • 89.9%: The decline in MoonLake's stock price on September 29, 2025, after the announcement of disappointing results from the VELA-2 trial.
  • $438 million: The amount secured by the Rosen Law Firm for investors in 2019 alone.
  • 2017: The year in which the Rosen Law Firm was ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements.

Sources:

  • GlobeNewswire, "Rosen Law Firm Announces Investigation of MoonLake Immunotherapeutics (NASDAQ: MLTX) Securities Claims" (Oct. 13, 2025)
  • Law360, "Laurence Rosen Named Titan of Plaintiffs' Bar" (2020)
  • ISS Securities Class Action Services, "Rosen Law Firm Ranked No. 1 for Number of Securities Class Action Settlements" (2017)
  • LinkedIn, @therosenlawfirm
  • Twitter, @therosenlawfirm
  • Facebook, @therosenlawfirm